Physical Exercise and Responses Measured by HIF-1 in COPD

Pulmonary Disease, Chronic Obstructive Clinical Trial

— ECOPDHIF-1  

Official title:

Effects of a Physical Exercise Program on the Responses Measured by HIF-1 Related to Ventilatory and Hematological Function in Patients With COPD Resident at 2600 m.s.n.m.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04955977
• Other study ID #: 47970
• Status: Recruiting
• Phase: N/A
• Start date: January 2022
• Est. completion date: June 2022

Study information

• Verified date: August 2021
• Source: Universidad Nacional de Colombia
• Contact: Wilder A Villamil-Parra, Therapist
• Phone: (57)3017564038
• Email: wavillamilp[@]unal.edu.co
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Despite being considered a potentially preventable disease, COPD is classified as one of the respiratory problems with the highest prevalence and socioeconomic impact. According to the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD), people with COPD require actions that optimize quality of life by improving lung function and increasing tolerance to fatigue.

Research such as those carried out by Semenza, establish that metazoan organisms such as the human species present biomolecular mechanisms for O2 homeostasis, based on transcriptional changes that allow regulating or modifying the responses necessary for the maintenance of the cellular metabolic functions. Hypoxia Induced Factor 1 (HIF-1) is the primary molecular mechanism for the regulation of O2-regulated genes in nuclear cells; Therefore, they promote adaptive mechanisms to hypoxia, through the generation of protein synthesis that favor processes such as erythropoiesis, angiogenesis, changes in oxidative metabolism and modification of the pulmonary vascular response.

Research carried out in cells of people with COPD exposed to environmental hypoxia by low oxygen pressure (PO2), have shown changes in the nuclear concentrations of HIF-1, affecting the transcriptional mechanisms of specific genes for Erythropoietin (EPO), the Factor of Vascular Endothelial Growth (VEFG) and therefore limit the generation of essential proteins for systemic responses. These transcriptional mechanisms are conditioned by the structural changes of chromatin seconded by the inhibition in the performance of histone enzymes, which influences the synthesis of proteins involved in metabolic, hematological and / or ventilatory processes as a response. to hypoxia. However, the concentration and effect of HIF 1 on the synthesis of EPO and VEGF and its relationship with spirometric and hematological tests have not been studied in COPD people who live in medium altitudes and who are additionally exposed to additional hypoxic stimuli such as exercise physical.

Although it is known that in COPD there is a decrease in the diffusion of O2 through the blood-gas barrier generating hypoxia and that with low PO2 there are biomolecular adaptations to favor oxygenation, perfusion, and metabolism; At the moment, the responses of HIF-1 and its effect on the generation of proteins associated with erythropoiesis and angiogenesis (EPO, FEVG) in people with COPD with physical exercise-based treatments are unknown.

Description:

1. General objective

To determine the effect of a physical exercise program on the responses mediated by HIF-1 in COPD patients resident at 2600 m.s.n.n.

2. Research question.

What is the effect of a physical exercise program on the responses mediated by HIF-1 in COPD patients resident at 2600 m.s.n.n?

3. Type of study.

It is presented as a quasi-experimental study with intra- and inter-group comparison before and after, with an external control group. Two observations will be made in time (pre and post test); Comparisons will be made intra-group and between groups, as follows:

Experimental group 1:

• G1: People with a diagnosis of COPD stratified in GOLD 1-2.

• O1: Measurement of HIF-1, HADC 7, EPO Synthesis, VGEF Synthesis, FEV1, Hemogram.

• X: Application of the physical exercise program.

• O2: Measurement HIF-1, HADC 7, EPO Synthesis, VGEF Synthesis, FEV1, Hemogram.

Experimental group 2:

• G2: People with a diagnosis of COPD stratified in GOLD 3-4.

• O3: Measurement HIF-1, HADC 7, EPO Synthesis, VGEF Synthesis, FEV1, Hemogram.

• X: Application of the physical exercise program.

• O4: Measurement HIF-1, HADC 7, EPO Synthesis, VGEF Synthesis, FEV1, Hemogram.

Control group:

• G3: People without a COPD diagnosis.

• O5: Measurement of HIF-1, HADC 7, EPO Synthesis, VGEF Synthesis, FEV1, Hemogram.

• X: Application of the physical exercise program.

• O6: Measurement HIF-1, HADC 7, EPO Synthesis, VGEF Synthesis, FEV1, Hemogram.

4. Phases of the study

Phase 1. Enrollment of participants and identification of baselines of HIF-1 measurements, synthesis of VEGF and EPO, Spirometry and Hemogram. Phase 2. Piloting and application of the physical exercise program in COPD residents in medium altitudes. Phase 3. Final measurement of HIF-1, synthesis of VEGF and EPO, Spirometry and Hemogram; Phase 4. Analysis of intra and intergroup results, writing final research report, socialization and publication of results.

The pilot test will be carried out with 10% of the initial sample calculated, in order to evaluate and refine the instruments to be used, verify the conditions of application of these and the procedures involved in obtaining the data, such as the times of registration of participants' participation in each session, execution of the physical exercise program and application of measurement tests.

5. Sample size.

A sample size calculation will be performed for longitudinal studies, using the Diggle formula for both differences between individuals and between groups, taking as a reference an expected effect, differences of 7.1, 4.96, 1.14 and 0.19 for the HIF-1; 1.6, 1.1; and finally 0.6, 0.3, 0.23 and 0.052 for the effect on VEGF and EPO protein synthesis. Similarly, variances (δ2) between 0.00004489 to 6.76 were considered depending on each effect measure as reported in the literature, Table 3 shows the expected variances and effect magnitudes in detail. Additionally, two measurements (pre and post) will be considered, for one (n = 4) for three comparison groups, with a type I error of α = 0.05, power P = 0.80 and exploring correlations (ρ) between -0.86 , 0.4, 0.47, 0.6, 0.79 or 0.8 depending on each parameter.

Below, you can see the different scenarios where the study sample is sufficient, it is thus that for the value of the expected effect magnitude in each of the response variables with the different scenarios of variances and correlations raised, the sample can be between 1 to 2630 participants. For the consideration of the present study, a sample of 27 participants will be taken in order to be able to observe different magnitudes with sufficient power. Because there may be losses to follow-up, a 20% increase was made for a total of 33 participants, 11 per group (66 total measurements).

6. Selection and enrollment of participants.

After obtaining the endorsements of the research and ethics committees of the National University of Colombia, the study population will be called; This will be done in person and via telephone to potential participants of the research project. The call mechanism will be by: 1. Lists of people attending rehabilitation programs of hospital institutions, 2. Open invitation to possible participants, through radio calls, newspapers and social networks, 3. Direct invitation to known people who comply with the inclusion criteria. Once the invitation is made, a screening will be carried out to identify the inclusion and exclusion criteria; Next, an appointment will be scheduled with the participant to fill out the informed consent.

7. Evaluation of the health condition and assignment of study groups.

People interested in participating in the research and who have signed informed consent, will be initially summoned for the medical and therapeutic evaluation of their health condition, therefore a clinical history format is presented for this project (Annex 3); At this time, spirometry will be applied to determine the degree of pulmonary compromise according to what is presented by the GOLD report 2019. Additionally, the physical fitness of the participants will be measured for the prescription of physical exercise.

8. Data analysis

8.1. Descriptive analysis

For the descriptive analysis of the characteristics of the population studied, the variables on the qualitative measurement scale will be described as proportional frequencies, the continuous variables will be described with measures of central tendency (mean and median) and dispersion (standard deviation, interquartile range). according to whether or not they present a normal distribution according to graphic (histograms, dispersion, among others) and numerical (Shapiro-Wilk) methods.

8.2 Baseline analysis

To compare the three groups (G1: COPD 1-2, G2: COPD 3-4, G3: without COPD). Parametric and non-parametric tests will be carried out according to the verification of a priori criteria. For comparisons between proportions, Chi2 or Fischer's exact will be carried out, for the comparison of continuous variables between the three groups an ANOVA or kruskal wallis test will be used.

8.3 Multivariate analysis

As a longitudinal method, a repeated measures analysis will be carried out for correlated data. For each of the continuous outcome variables, the analysis will be performed with fixed effects (marginal) models. The evaluation of the assumption of normal distribution of the variables will be carried out using graphic methods (histograms, box plots and QQ graphs).

In the model, the main exposure will be included as covariates, referring to the group it belongs to (G1: COPD 1-2, G2: COPD 3-4, G3: without COPD). The time will be taken as a continuous variable according to the minutes between each of the measurements, for which its linearity and its interactions with the covariates of interest will be evaluated, in case of not complying with this assumption it will be categorized based on the measurements carried out, considering the baseline measurement as a reference and the evaluation of possible interaction terms will be carried out. For the variables with normal distribution, the restrictive model of maximum likelihood (REML) will be used to select the best correlation matrix; later, to select the covariates to keep in the model, the maximum likelihood estimate (MLE) will be used. The selection of the best model will be based on the lower value of the Akaike information criterion (AIC) and the Bayesian evaluation criterion (BIC) after having evaluated the interactions and the non-linear terms. For conditional models, models with intercept and slopes will be used. If it does not present a normal distribution, a generalized equation estimation model (GEE) with an unstructured matrix will be implemented. A residual analysis will be performed on all final models. With the above, it will be possible to evaluate the effects both within and between groups with a more robust model to analyze the outcome measures and control for possible confounding variables.

9. Intervention (Physical exercise program for people with COPD.)

The physical exercise program is proposed according to the existing scientific evidence and the recommendations of the GOLD 2019. This program will be based on an 8-week macro training cycle with 3 sessions per week for a total of 24 out-of-hospital training sessions. It will consist of 4 steps, each one consisting of 2 training microcycles or 6 work sessions; Training of conditional and coordinative physical qualities will be carried out in each step, and additionally with health education sessions.

10. Control of biases

10.1. Control and management of internal invalidation sources

• Threat-History. Actions to be taken: Participants in the experimental groups experience the same event, being people with COPD exposed to altitude hypoxia due to being residents at 2060 meters above sea level, with stratification of disease severity (GOLD 3 - 4).

• Threat - Maturation. Actions to be taken: Establishment of inclusion and exclusion criteria. Participants over 40 years of age with complete biological maturation.

• Threat-Instability of the measuring instrument. Actions to be taken: The instruments to be used in the collection of information have validity and reliability; They have been used in multiple investigations related to the subject and are strategies.

• Threat-Instability of the experimental environment. Actions to be carried out: the environmental conditions are the same for all the research participants since they will be applied at 2,600 meters above sea level in the city of Bogotá D.C. The intervention has a defined protocol that will be applied by the same researcher to all study participants.

• Threat: Instrumentation. Actions to be taken: the same measurement instruments will be applied to all research participants regardless of the stratification of the disease or the assignment to the control group.

• Threat - Selection. Actions to be taken: Participants will be established in groups according to the GOLD 3 or GOLD 4 disease stratification.

• Threat-attrition. Actions to be taken: Calculation of the sufficient sample size and carried out by a statistician outside the investigation, taking into account 20% of possible attrition.

10.2 Control and management of sources of external invalidation

• Threat-Reactive or interaction effect of the tests. Actions to be taken: The instruments that will be used in the collection of information have validity and reliability.

• Threat-Effect of interaction between selection errors and experimental treatment. Actions to be taken: Inclusion and exclusion criteria are established, which rule out people with aspects that can be inferred from the research results.

• Threat-Interference from multiple treatments. Actions to be taken: A single physical exercise program will be carried out for all the research participants.

• Threat: Impossibility of replicating the treatments: Actions to be taken: Detailed description of the content of the physical exercise program.

• Threat-Interaction between history or place and the effects of the experimental treatment. Actions to be carried out: The investigation will be carried out in the same place and laboratory, located at 2,600 meters above sea level, in the city of Bogotá D.C.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 33
• Est. completion date: June 2022
• Est. primary completion date: March 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Adult person, over 40 years of age, both sexes, resident in medium altitudes or 2,600 meters above sea level in the last 2 years.

• People with a diagnosis of COPD categorized in GOLD 1,2,3 and 4, with no record of respiratory crises in the last 3 months.

• People with a diagnosis of COPD categorized by lung function in GOLD 1,2,3 and 4 and by severity of symptoms in A, B and C, without the need for supplemental oxygen.

• People with a diagnosis of COPD settled and domiciled for a minimum time of 14 months at moderate altitudes or 2600 m.a.s.l.

• People who have read and signed informed consent and who have membership in a mandatory health plan.

Exclusion Criteria:

• People with a medical diagnosis of anemia, liver disease, chronic kidney disease, rheumatological diseases or a history of gastrointestinal bleeding in the last 2 months.

• People with a diagnosis of COPD who have a history of kidney or liver transplantation.

• People with a diagnosis of COPD who present severity of symptoms and/or respiratory exacerbations categorized in D presenting an mMRC > 2 and CAT > 10 with >1 hospitalization requirements.

• People who are under pharmacological management with erythropoietin (EPO), antibiotics and / or steroids on a chronic basis.

• People with musculoskeletal injuries that limit the execution of the physical training program or that present medical restrictions for the execution of physical exercise.

• People with a diagnosis of COPD who record active smoking.

• People who are participating in research related to medical, pharmacological or physiotherapeutic intervention protocols.

Related Conditions & MeSH terms

• Pulmonary Disease, Chronic Obstructive

Intervention

Other:
• Physical exercise program
Step 1 • Diaphragmatic reeducation: • Aerobic capacity: Intensity: zone 2, 60% HRMax, 4-6 / 10 Borg Scale; Charge: 20 m. Step 2 • Aerobic capacity: Intensity: zone 2, 65% HRMax, 4-6 Borg Scale; Charge: 25 m. • Muscular strength: Method: Pyramidal; Intensity: 3-4 / 10 Omni-Res; Load: 20% 1RM; Series: 3; Reps: 1. • Flexibility and elasticity: Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s. Step 3 • Aerobic capacity: Intensity: zone 3, 70% HRMax, 5-6 / 10 Borg scale, Load: 25 m. • Muscular strength: Method: Pyramidal; Intensity: 4-5 / 10 Omni-Res; Load: 30% 1RM; Series: 4; Reps: 10. • Flexibility and elasticity: Method: active stretching; Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s. Step 4 •Aerobic capacity: Intensity: zone 3, 75% HRMax, 6-7 / 10 Borg scale, Load: 30 m. • Muscular strength: Intensity: 5-6 / 10 Omni-Res; Load: 40-50% 1RM; Series: 4 s; Reps: 13. • Flexibility and elasticity: Method: active stretching; Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s.
• Health education in COPD
Week 1-2: Health education: COPD and respiratory care at home. Week 3-4: Importance of daily physical activity in COPD. Week 5-6: Early Signs of COPD Exacerbation and Action Plan Week 7-8: Use and care of respiratory devices at home.

Locations

Country	Name	City	State
Colombia	National university of Colombia	Bogotá	Cundinamarca

Sponsors (2)

Lead Sponsor	Collaborator
Universidad Nacional de Colombia	University of Barcelona

Country where clinical trial is conducted

Colombia, 

References & Publications (8)

Chen LJ, Xu W, Li YP, Ma LT, Zhang HF, Huang XB, Yu GG, Ma XQ, Chen C, Liu YH, Wu J, Wang LJ, Xu Y. Lycium barbarum Polysaccharide Inhibited Hypoxia-Inducible Factor 1 in COPD Patients. Int J Chron Obstruct Pulmon Dis. 2020 Aug 24;15:1997-2004. doi: 10.2147/COPD.S254172. eCollection 2020. — View Citation

Fu X, Zhang F. Role of the HIF-1 signaling pathway in chronic obstructive pulmonary disease. Exp Ther Med. 2018 Dec;16(6):4553-4561. doi: 10.3892/etm.2018.6785. Epub 2018 Sep 21. — View Citation

Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005 May 12;352(19):1967-76. — View Citation

Kanazawa H, Yoshikawa J. Elevated oxidative stress and reciprocal reduction of vascular endothelial growth factor levels with severity of COPD. Chest. 2005 Nov;128(5):3191-7. — View Citation

Lee SW, Hwang HH, Hsu PW, Chuang TY, Liu CW, Wu LS. Whole-genome methylation profiling from PBMCs in acute-exacerbation COPD patients with good and poor responses to corticosteroid treatment. Genomics. 2019 Dec;111(6):1381-1386. doi: 10.1016/j.ygeno.2018.09.010. Epub 2018 Sep 21. — View Citation

Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE. 2007 Oct 9;2007(407):cm8. Review. — View Citation

Tao H, Luo W, Pei H, Zhu S, Zhang M, Chen B, He J, Zhang M, Zhou R. [Expression and significance of hypoxia-inducible factor-1a in patients with chronic obstructive pulmonary disease and smokers with normal lung function]. Xi Bao Yu Fen Zi Mian Yi Xue Za — View Citation

To M, Yamamura S, Akashi K, Charron CE, Haruki K, Barnes PJ, Ito K. Defect of adaptation to hypoxia in patients with COPD due to reduction of histone deacetylase 7. Chest. 2012 May;141(5):1233-1242. doi: 10.1378/chest.11-1536. Epub 2011 Dec 15. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Nuclear concentration of HIF-1	Changes in the nuclear concentration of hypoxia-inducible factor (HIF-1) in plasma. For this, an enzyme-linked immunosorbent assay (ELISA) will be executed using specific antibodies to immobilize the study proteins on a plate for their subsequent detection, with chemiluminescence detection.	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.
Primary	VEGF protein synthesis.	Changes in the synthesis of the Vascular Endoletial Growth Factor (VEGF) protein in plasma. For this, an enzyme-linked immunosorbent assay (ELISA) will be executed using specific antibodies to immobilize the study proteins on a plate for their subsequent detection, with chemiluminescence detection.	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.
Primary	Synthesis of EPO protein.	Changes in the synthesis of Erythropoietin (EPO) protein synthesis in plasma. For this, an enzyme-linked immunosorbent assay (ELISA) will be executed using specific antibodies to immobilize the study proteins on a plate for their subsequent detection, with chemiluminescence detection.	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.
Secondary	Arm Curl Test	The total number of times the dominant arm is flexed and extended during 30 seconds.	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.
Secondary	Chair Stand Test	The total number of times the person gets up and sits in the chair for 30 seconds.	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.
Secondary	6 Minute WalK Test	Distance traveled by the person be walking on flat ground for 6 minutes	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.
Secondary	Chair-Sit and Reach Test	While sitting, the person will touch the leg that is stretched out with their hands. The distance in cm from the tip of the fingers to the top of the shoe is measured while sitting. If the fingers of the hands do not reach the foot, the distance will be measured in negative values (-) and if the fingers of the hands exceed the foot, the distance will be recorded in positive values (+)	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.
Secondary	Back Scratch Test	They put their hands touching their back "as if it were scratching." The distance between the tips of the middle fingers of the two hands. If the fingers of the hands do not touch, the distance will be measured in negative values (-). If the fingers of the hands overlap, the distance is recorded in positive values (+).	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.
Secondary	8-Foot up and go Test	The person gets up from the chair and walks as fast as possible by a line to surround a cone located 2.44 meters away and must sit again. The time (minutes and seconds) the person spends doing the exercise is measured.	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.
Secondary	Forced expired volume in the first second (FEV1)	Volume of air expelled during the first second of maximum expiration, carried out after maximum inspiration. Percentage of air expelled in the first second of expiration.	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.
Secondary	Functional Vital Capacity (FVC)	Maximum volume of expired air, with the maximum possible effort, starting from a maximum inspiration. It is expressed as a volume in milliliters.	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.
Secondary	FEV1/FVC ratio	Relationship between Forced Expiratory Volume in the first second (FEV1) and Forced Vital Capacity (FVC). It is expressed as a percentage.	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.
Secondary	Erythrocyte count	Percentage of reticulocyte volume in a given volume of blood. Reticulocytes / blood volume * microliter.	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.
Secondary	Medium corpuscular volume (MCV)	Average size of red blood cells. MCV(fl) = Hematocrit (%) x 10 / Red blood cells (x 10^6/ul)	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.
Secondary	Mean Corpuscular Hemoglobin (HCM)	Average hemoglobin content of each red cell. HCM (pg) = Hemoglobin (g/dl) x 10/Red blood cells (x10^6/ul)	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.
Secondary	Blood hemoglobin (Hb)	Amount of hemoglobin in blood sample expressed in grams per deciliter. Hb = g/dL	1. Initial measurement (week 0) before the application of the physical exercise program. 2. Final measurement (week 8) after completion of the intervention program.

External Links

•   2021 GLOBAL STRATEGY FOR PREVENTION, DIAGNOSIS AND MANAGEMENT OF COPD